Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patheon To Merge With DSM Pharma Business To Create New Company

This article was originally published in The Pink Sheet Daily

Executive Summary

The newly created company hopes to be a full-service outlet for its pharmaceutical clients now that its offerings will be in more territories and encompass more services, including APIs, dosage and softgel formulations.

You may also be interested in...



IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Deals Of The Week Wonders: Will Pharma Ever Pay More For Companion Diagnostics?

Partnerships between Lilly/Qiagen and BioMarin/Myriad highlight the increasing pace of deals to develop companion diagnostics as the importance of biomarkers and tests to drug development increases. In other deals Clovis buys Eos, Amicus buys Callidus and Versant gives Celgene and Bayer options to acquire drug assets.

Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO

Shortly after the market closed on June 30, Biogen Idec and Exelixis confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos taking the helm of the Big Biotech July 15

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel